protoporphyrin ix has been researched along with Actinic Keratosis in 29 studies
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 9.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "Dosimetry for aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy of actinic keratosis was examined with an optimized fluorescence dosimeter to measure PpIX during treatment." | 7.80 | Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Zhao, Y, 2014) |
| "We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching." | 7.79 | Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. ( Barge, J; Kasraee, B; Piffaretti, F; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| " Protoporphyrin IX (PpIX) accumulation becomes lower after 3 h in pulse-PDT than in classical PDT, but pulse-PDT still has full treatment effect on actinic keratosis (AK)." | 5.27 | Protoporphyrin IX formation after application of methyl aminolevulinate on the face and scalp with and without prior curettage. ( Bieliauskiene, G; Heerfordt, IM; Wulf, HC, 2018) |
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 5.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| " Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated." | 5.19 | Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014) |
| "Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) or its methyl ester (MAL) is a very effective method to treat actinic keratosis (AK)." | 4.85 | New aspects in photodynamic therapy of actinic keratoses. ( Moor, AC; Smits, T, 2009) |
| "Dosimetry for aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy of actinic keratosis was examined with an optimized fluorescence dosimeter to measure PpIX during treatment." | 3.80 | Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Zhao, Y, 2014) |
| "We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching." | 3.79 | Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. ( Barge, J; Kasraee, B; Piffaretti, F; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| "Because of the retrospective study design not all factors that may influence pain (eg, protoporphyrin IX fluorescence) were recorded." | 3.76 | Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. ( Denk, K; Enk, A; Gholam, P; Hartmann, M; Sehr, T, 2010) |
| "Pain is the main acute adverse event during photodynamic therapy of skin lesions." | 2.74 | Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study. ( Haedersdal, M; Wiegell, SR; Wulf, HC, 2009) |
| " Protoporphyrin IX synthesis and photobleaching kinetics allow monitoring clinical PDT which facilitates individual-based PDT dosing and improvement of clinical treatment protocols." | 1.42 | Correction for tissue optical properties enables quantitative skin fluorescence measurements using multi-diameter single fiber reflectance spectroscopy. ( Amelink, A; Hoy, CL; Middelburg, TA; Neumann, HA; Robinson, DJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 25 (86.21) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ruiz, AJ | 2 |
| Allen, R | 1 |
| Giallorenzi, MK | 1 |
| Samkoe, KS | 1 |
| Shane Chapman, M | 1 |
| Pogue, BW | 4 |
| LaRochelle, EPM | 1 |
| Gunn, JR | 1 |
| Hull, SM | 1 |
| Hasan, T | 3 |
| Chapman, MS | 3 |
| Manley, M | 2 |
| Collins, P | 2 |
| Gray, L | 2 |
| O'Gorman, S | 1 |
| McCavana, J | 2 |
| Maytin, EV | 3 |
| Anand, S | 1 |
| Riha, M | 1 |
| Lohser, S | 1 |
| Tellez, A | 1 |
| Ishak, R | 1 |
| Karpinski, L | 1 |
| Sot, J | 1 |
| Hu, B | 1 |
| Denisyuk, A | 1 |
| Davis, SC | 3 |
| Kyei, A | 1 |
| Vidimos, A | 1 |
| Heerfordt, IM | 2 |
| Bieliauskiene, G | 1 |
| Wulf, HC | 7 |
| McLellan, LJ | 1 |
| O'Mahoney, P | 1 |
| Khazova, M | 1 |
| Higlett, M | 1 |
| Ibbotson, SH | 2 |
| Eadie, E | 1 |
| Piffaretti, F | 1 |
| Zellweger, M | 1 |
| Kasraee, B | 1 |
| Barge, J | 1 |
| Salomon, D | 1 |
| van den Bergh, H | 1 |
| Wagnières, G | 1 |
| Petersen, B | 3 |
| Wiegell, SR | 6 |
| Kanick, SC | 2 |
| Zhao, Y | 2 |
| Middelburg, TA | 1 |
| Hoy, CL | 1 |
| Neumann, HA | 2 |
| Amelink, A | 1 |
| Robinson, DJ | 1 |
| Salas-García, T | 1 |
| López-Gómez, A | 1 |
| Dorado-Fernández, M | 1 |
| Ruiz-Martínez, J | 1 |
| Kulyk, O | 1 |
| Moseley, H | 1 |
| Valentine, RM | 1 |
| Samuel, ID | 1 |
| Sheehan, KL | 1 |
| O'Gorman, SM | 1 |
| Clowry, J | 1 |
| Kavanagh, A | 1 |
| Lally, A | 1 |
| Chen, J | 1 |
| Zhang, Y | 1 |
| Wang, P | 1 |
| Wang, B | 1 |
| Zhang, G | 1 |
| Wang, X | 1 |
| Nissen, CV | 1 |
| Mikkelsen, CS | 1 |
| Ibbotson, S | 1 |
| Stones, R | 1 |
| Bowling, J | 1 |
| Campbell, S | 2 |
| Kownacki, S | 1 |
| Sivaramakrishnan, M | 1 |
| Valentine, R | 1 |
| Morton, CA | 1 |
| Gandy, J | 1 |
| Labadie, B | 1 |
| Bierman, D | 1 |
| Zachary, C | 1 |
| Smits, T | 2 |
| van Laarhoven, AI | 1 |
| Staassen, A | 1 |
| van de Kerkhof, PC | 1 |
| van Erp, PE | 1 |
| Gerritsen, MJ | 1 |
| Haedersdal, M | 1 |
| Moor, AC | 1 |
| Tyrrell, J | 1 |
| Curnow, A | 3 |
| Gholam, P | 1 |
| Denk, K | 1 |
| Sehr, T | 1 |
| Enk, A | 1 |
| Hartmann, M | 1 |
| Tyrrell, JS | 1 |
| Morton, C | 1 |
| Campbell, SM | 1 |
| van der Beek, N | 1 |
| de Leeuw, J | 1 |
| Demmendal, C | 1 |
| Bjerring, P | 1 |
| Fabricius, S | 1 |
| Heydenreich, J | 1 |
| Enk, CD | 1 |
| Rosso, S | 1 |
| Bäumler, W | 1 |
| Baldursson, BT | 1 |
| Blake, E | 1 |
| Allen, J | 1 |
| Thorn, C | 1 |
| Shore, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737] | 43 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| Fluorescence and Thermal Imaging of the Skin Before and During Photodynamic Therapy[NCT03167762] | 18 participants (Actual) | Interventional | 2017-06-22 | Completed | |||
| [NCT02520700] | 22 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| The Study of Plum-blossom Needling Enhancing Efficacy of Aminolevulinic Acid-photodynamic Therapy for Actinic Keratosis: a Randomized and Multi-center Clinical Trial[NCT03596619] | 250 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for protoporphyrin ix and Actinic Keratosis
| Article | Year |
|---|---|
Daylight photodynamic therapy.
Topics: Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Meteorological Concepts; Photochemotherapy; Photo | 2015 |
New aspects in photodynamic therapy of actinic keratoses.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agents; Protopo | 2009 |
13 trials available for protoporphyrin ix and Actinic Keratosis
| Article | Year |
|---|---|
5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial.
Topics: Apoptosis; Biomarkers; Biopsy; Fluorouracil; Heme; Humans; Keratosis, Actinic; Photochemotherapy; Ph | 2018 |
Protoporphyrin IX formation after application of methyl aminolevulinate on the face and scalp with and without prior curettage.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Face; Female; Humans; Keratosis, Actinic; M | 2018 |
Light protection of the skin after photodynamic therapy reduces inflammation: an unblinded randomized controlled study.
Topics: Aminolevulinic Acid; Drug Eruptions; Erythema; Female; Fluorescence; Humans; Keratosis, Actinic; Mal | 2014 |
Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; C | 2014 |
Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Optical Imaging; Photosensit | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Artificial White Light vs Daylight Photodynamic Therapy for Actinic Keratoses: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Facial Dermatoses; Follow-Up Studies; Humans; Keratosi | 2016 |
Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Fluorescence; Hum | 2016 |
Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Drug Eruptions; Erythema; Female; Fluoresce | 2017 |
Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study.
Topics: Aged; Cold Temperature; Female; Fluorescence; Humans; Keratosis, Actinic; Male; Middle Aged; Pain; P | 2009 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo | 2011 |
PpIX fluorescence combined with auto-fluorescence is more accurate than PpIX fluorescence alone in fluorescence detection of non-melanoma skin cancer: an intra-patient direct comparison study.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Bowen's Disease; Carcinoma; Carcinoma, Basal Cell; False Neg | 2012 |
Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Oxygen; Pho | 2013 |
14 other studies available for protoporphyrin ix and Actinic Keratosis
| Article | Year |
|---|---|
Smartphone-based dual radiometric fluorescence and white-light imager for quantification of protoporphyrin IX in skin.
Topics: Humans; Keratosis, Actinic; Light; Skin; Smartphone | 2023 |
Smartphone fluorescence imager for quantitative dosimetry of protoporphyrin-IX-based photodynamic therapy in skin.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Equipment Design; Humans; Imaging, Three-Di | 2019 |
Quantifying the radiant exposure and effective dose in patients treated for actinic keratoses with topical photodynamic therapy using daylight and LED white light.
Topics: Administration, Topical; Aminolevulinic Acid; Humans; Keratosis, Actinic; Light; Lighting; Male; Pho | 2018 |
Ultraviolet radiation exposure during daylight Photodynamic Therapy.
Topics: Dose-Response Relationship, Drug; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing Ag | 2019 |
Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy.
Topics: Aged; Aminolevulinic Acid; Fluorescence; Humans; Keratosis, Actinic; Middle Aged; Pain; Pain Measure | 2013 |
Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.
Topics: Humans; Keratosis, Actinic; Phantoms, Imaging; Photochemotherapy; Pilot Projects; Protoporphyrins; R | 2014 |
Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.
Topics: Humans; Keratosis, Actinic; Phantoms, Imaging; Photochemotherapy; Pilot Projects; Protoporphyrins; R | 2014 |
Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.
Topics: Humans; Keratosis, Actinic; Phantoms, Imaging; Photochemotherapy; Pilot Projects; Protoporphyrins; R | 2014 |
Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.
Topics: Humans; Keratosis, Actinic; Phantoms, Imaging; Photochemotherapy; Pilot Projects; Protoporphyrins; R | 2014 |
Correction for tissue optical properties enables quantitative skin fluorescence measurements using multi-diameter single fiber reflectance spectroscopy.
Topics: Aged; Female; Fiber Optic Technology; Fluorescence; Humans; Keratosis, Actinic; Male; Optical Imagin | 2015 |
Plum-blossom needling promoted PpIX fluorescence intensity from 5-aminolevulinic acid in porcine skin model and patients with actnic keratosis.
Topics: Acupuncture Therapy; Aged; Aminolevulinic Acid; Animals; Female; Fluorescent Dyes; Humans; In Vitro | 2016 |
A consensus on the use of daylight photodynamic therapy in the UK.
Topics: Aminolevulinic Acid; Consensus; Humans; Keratosis, Actinic; Light; Male; Photochemotherapy; Photosen | 2017 |
Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time.
Topics: Aminolevulinic Acid; Face; Humans; Keratosis, Actinic; Male; Middle Aged; Pain; Photochemotherapy; P | 2017 |
Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells.
Topics: Administration, Topical; Aminolevulinic Acid; Humans; Keratosis, Actinic; Photochemotherapy; Photose | 2009 |
Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT.
Topics: Aged; Aminolevulinic Acid; Dose-Response Relationship, Drug; Fluorescence; Humans; Keratosis, Actini | 2010 |
Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cosmetic Techniques; Female; Humans; Keratosis, | 2010 |
Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations.
Topics: Aminolevulinic Acid; Dose-Response Relationship, Radiation; Europe; Geography, Medical; Humans; Isra | 2013 |